Trial Profile
Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms GETUG P07; OLIGOPELVIS
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
- 30 Aug 2016 Planned End Date changed from 1 Sep 2026 to 1 Jul 2026.
- 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.